GDTC — CytoMed Therapeutics Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1873093 ·
Last close
$1.15
Market Cap
$13.61M
52W High
$1.39
52W Low
$0.68
ADV30
21,274
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 7,984,953 | 2,095,489 | 1,131,286 |
| Dec 2024 | — | — | — | — | 10,067,749 | 4,970,367 | 1,023,960 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-18,828,592
Inventory
—
Receivables
$132,054
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$860,848
EBITDA
$-3,849,627
Free Cash Flow
$-2,715,337
Enterprise Value
$12,062,426
Total Cash
$2,095,489
Total Debt
$482,562
Shares Out
11,832,835
Trailing EPS
$-0.27
Book Value
$0.43
ROE
-50.3%
ROA
-29.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 324,387 | -4,241,678 | -3,980,457 | 7,984,953 | 1,131,286 | — | -3,697,463 |
| Dec 2024 | 69,501 | -3,130,528 | -2,516,698 | 10,067,749 | 1,023,960 | — | -2,709,929 |
| Dec 2023 | 0 | -3,842,846 | -4,132,896 | 12,368,870 | 1,124,715 | — | -3,531,196 |
| Dec 2022 | 0 | -1,856,566 | -3,131,209 | 5,227,058 | 4,640,760 | — | -1,398,409 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.15
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TOVX | Theriva Biologics, Inc. | $13.63M | $0.30 | — |
| HOTH | Hoth Therapeutics, Inc. | $13.55M | $0.71 | — |
| BLRX | BioLineRx Ltd. | $13.75M | $3.16 | — |
| CYCN | Cyclerion Therapeutics, Inc. | $13.86M | $3.20 | — |
| ERNA | Ernexa Therapeutics Inc. | $13.33M | $11.43 | — |
News headlines (Yahoo Finance, 1h cache)
CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects
2026-02-06 18:05 · Yahoo
Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progress
2026-01-29 15:11 · Yahoo
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
2026-01-28 15:00 · Yahoo
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
2026-01-13 13:00 · Yahoo
CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogene
2025-12-08 13:00 · Yahoo
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
2025-11-18 13:00 · Yahoo
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
2025-11-06 13:00 · Yahoo
CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
2025-10-22 12:00 · Yahoo
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
2025-10-14 12:00 · Yahoo
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leuk
2025-10-02 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.